Organic Active Ingredients TRIZ Cases

A rifaximin HPMC-AS solid dispersion improves therapeutic effectiveness in cirrhosis by reducing hospitalization time and mortality.

A bispecific anti-HER2 antibody paired with docetaxel albumin cuts infusion time and hospital stay while preserving antitumor efficacy.

Novel indazole compounds inhibit PKMYT1 to disrupt the G2/M checkpoint while improving safety and pharmacokinetic stability in cancer therapy.

Novel ionizable lipid compositions improve intracellular RNA delivery while reducing immunogenicity and increasing safety and specificity.

A thiazole small-molecule inhibitor targets IL-17A for oral autoimmune treatment, avoiding injection-based antibody dosing.

GSK3 inhibitors reduce DNA, vascular, and inflammatory damage to protect lung tissue from radiation-induced pulmonary fibrosis.

Targeted ligand-drug conjugates use camptothecin derivatives and linkers to preserve antitumor activity while reducing toxicity.

Fused pyrrole and pyridine compounds inhibit Myt1, reduce tumor proliferation, and help overcome chemotherapy resistance in Myt1-dependent cancers.

Small-molecule α4β7 antagonists replace injectable antibodies with oral formulations while preserving integrin inhibition for inflammatory disease treatment.

Respirable dry powder surfactants enable pulmonary delivery without endotracheal intubation while stabilizing alveoli and reducing surface tension.

A dual nonionic surfactant system keeps vitamin D3 stable in higher-water topical formulations while preserving spreadability and efficacy.

Dual EGFR and Type I IFN modulation helps treat EGFR wild-type NSCLC and counter secondary resistance to EGFR inhibition.

Bicyclic nitrogen heterocycles tune substituents and ring structure to improve SIK2 selectivity and pharmacokinetic potential in therapy.

Poloxamer 407 stabilizes moxifloxacin and triamcinolone in an ophthalmic composition to prevent precipitation and preserve postoperative efficacy.

Controlled granule surface area, binder, lubricant, and drying conditions help ferric citrate tablets dissolve rapidly while staying intact.

Modified dsRNA targets MASP-2 expression to improve complement-mediated disease treatment while limiting off-target effects and immunogenicity.

Dual-target pyrimido-macroheterocyclic compounds address weak single-target WEE1 efficacy by inhibiting WEE1 and Yes with improved PK profiles.

Encapsulated nucleic acids encoding HTLV-1 Gag, Tax, and HBZ antigens use a lipid complex to trigger immune responses for prevention and treatment.

A Formula (Ie) IDH inhibitor blocks α-KG conversion to D-2-HG, reducing oncometabolite buildup linked to hypermethylation and cancer.

A two-phase granule and powder blend stabilizes amlodipine, ramipril, and rosuvastatin while preserving uniform release and bioavailability.

A DNA aptamer with artificial Ds bases enables selective sFLT-1 removal in apheresis, avoiding nonspecific binding and antibody instability.

Structural changes in azepine benzodiazepines raise GABAA receptor affinity to improve sedative efficacy while reducing toxicity and side effects.

Natural polysaccharides inhibit influenza entry and replication while reducing viral load, tissue damage, and side effects.

Chiral resolution and selective alkylation raise pyrazolopyrazine purity and yield while avoiding costly catalysts and chromatography.

Nonionic surfactants and EDTA keep preservative-free tafluprost soluble and stable while limiting absorption to polyethylene eye-drop containers.

A stable tablet combining tenofovir alafenamide and emtricitabine cuts excipient load while maintaining bioequivalence and efficacy.

Anchored ApoE or amyloid-beta recognition peptides help liposomes cross the BBB selectively while preserving barrier integrity and limiting off-target delivery.

HPMCAS and TPGS enable an oral paclitaxel solid dispersion that improves solubility and bioavailability while avoiding Cremophor EL toxicity.

A biodegradable liquid-solid ocular composition enables simple injection with slow drug release, reducing repeat procedures, pain, and infection risk.

An aqueous delgocitinib cream improves topical treatment of cutaneous lupus by balancing formulation stability, lesion control, and safety.

Selective pyrazolopyrimidinone PDE2 inhibitors improve cognitive and motor function while addressing potency and side-effect tradeoffs.

Targeting P2X3 and P2X2/3 receptors with a diaminopyrimidine compound relieves endometriosis pain without hormonal therapy side effects.

Functionalized long-chain dicarboxylic acids address kidney fibrosis and CKD with anti-inflammatory effects and fewer side effects.

Codon-optimized SMN cassettes with miRNA target sequences raise SMN expression while limiting AAV immune response, liver toxicity, and DRG damage.

A shikimic acid and Prunus Mume biocomplex improves solubility and stability while modulating 5α-reductase type I to manage hormonal acne.

A GM-CSF, sucrose octasulfate, and hyaluronic acid hydrogel improves chronic wound healing and supports deeper topical delivery.

Combining seleno amino acid compounds with cytotoxicity-enhancing agents helps inhibit liver and pancreas cancer growth with fewer side effects.

AAV vectors deliver anti-VEGF genes and RNA interference to sustain ocular angiogenesis treatment while reducing repeated intravitreal injections.

Selective deuteration of arachidonic acid slows bis-allylic oxidation, lowering pro-inflammatory mediators and enabling long-term inflammation control.

Selective N-heterocycle tryptamine derivatives improve brain receptor targeting, extend dosing intervals, and reduce systemic side effects.

Bifunctional MDM2-binding compounds recruit target proteins for ubiquitination and degradation, expanding druggable targets with better specificity.

A small-molecule biphenyl PD-L1 modulator improves oral absorption and prolongs tumor exposure to reduce injection-related side effects.

Controlled polymorph crystallization improves benzodiazepinone solubility, bioavailability, and melting point for pharmaceutical use.

Novel macrocyclic compounds improve IRAK-4 inhibition for autoimmune and inflammatory treatment while maintaining selective kinase targeting and low genetic toxicity.

Sustained-release polymer-encapsulated drug particles on balloon coatings help treat recurrent strictures while reducing repeat interventions.

Blocking GCN2 and PERK stress signaling prevents ASNS compensation, improving L-asparaginase sensitivity and immune activation in cancer cells.

Biodegradable hyaluronic acid fibers fill periodontal pockets, block bacterial recolonization, and degrade on schedule to support healing.

Novel triazolopyrazine compounds inhibit Syk to curb autoantibody production, mast cell degranulation, and osteoclast activity.

gp130 antagonist compounds block IL-6 signaling to reduce inflammation and cartilage degeneration in osteoarthritis, delaying joint damage.

Cationic lipid nanoparticles encapsulate codon-optimized mRNA to overcome lung mucus barriers and boost protein expression for pulmonary therapy.

Bevemipretide is used to slow ONL thinning and retinal thickness loss while protecting photoreceptors from light- and age-induced damage.

Antibody-linked PI3K/PIKK inhibitors target tumor cells and release payloads selectively, improving anti-tumor activity while limiting toxicity.

Combining BI853520 with KRAS or MEK inhibitors overcomes persistent KRAS signaling and drives sustained regression in KRAS-mutant tumors.

Chemically modified ACSL4 antisense oligonucleotides suppress ferroptosis during ischemia-reperfusion, protecting neurons in stroke models.

High-compression and sintered polymer matrices create a tamper-resistant dosage form that resists crushing while maintaining sustained drug release.

Combining BAIBA with creatine helps reduce ammonia, lactate, and muscle damage markers to improve endurance and speed post-exercise recovery.

Monthly 75-85 mg ISIS 681257 dosing lowers Lp(a) in established cardiovascular disease while reducing patient exposure and dosing burden.

G2 synchronization, p53 activation, and PLK1 inhibition enable stable senescent cell purification and selective removal with glutaminase inhibition.

Bulk-manufactured HER2 CAR-NK cells enable immediate, repeat dosing for HER2+ cancers while avoiding HLA matching and graft-versus-host risk.

Delayed-release vitamin C with Lactobacillus rhamnosus targets the large intestine to raise Bifidobacterium and related beneficial bacteria.

Activated-platelet-binding nanoparticles bypass endothelial barriers to raise tumor drug accumulation while limiting off-target toxicity.

Targeting PARG with tricyclic heterocyclic inhibitors helps overcome PARP inhibitor resistance by sensitizing cancer cells to DNA damage.

Cyclic compounds target the MALT1 protease active site to inhibit CBM signaling and treat cancer, autoimmune, and inflammatory disorders.

Using dodecylphosphocholine, this nalmefene nasal spray improves mucosal absorption for rapid onset and easier emergency administration.

Antisense oligonucleotide gapmers bind target mRNA to modulate pro- and anti-fibrotic protein expression with safer, titratable fibrosis treatment.

Heterocyclic KRAS inhibitors use modular substituent tuning to improve potency and selectivity while preserving favorable pharmacokinetics.

By targeting allosteric regions outside the ATP site, these alkynyl quinazolines inhibit ErbB mutants while avoiding paradoxical activation.

Passive frequency-domain analysis of spontaneous muscle movements enables continuous neuromuscular block assessment without electrical stimulation.

Maintains VMAT2 inhibitor plasma levels by avoiding or discontinuing strong CYP3A4 inducers that can cause sub-therapeutic exposure.

Meal-specific waiting intervals for oral edaravone reduce food-related pharmacokinetic variability and support more consistent drug absorption.

A dehydrated kombucha cellulose matrix reactivates on contact to deliver antimicrobial protection, moisture retention, and adhesive wound coverage.

dsRNA agents silence C3 mRNA through RISC cleavage, offering less invasive complement suppression for CAD, PNH, and related disorders.

TRPV4 antagonists and MTx4 peptides help protect retinal ganglion cells in glaucoma beyond pressure-lowering treatment alone.

Purification and substitution control remove propylene glycol, endotoxin, and free beta-cyclodextrin for chronic intrathecal use.

A PEGylated lipid forms a hydrated shield on cationic liposomes, reducing serum protein adsorption while preserving nucleic acid loading.

Ligand-directed heterocyclic PROTACs recruit E3 ligase to degrade BCL6, addressing poor target removal in cancer and autoimmune therapy.

Chromanone compounds bind HLA-DR to block autoantigen presentation to T cells, reducing autoimmune tissue damage and symptoms.

A defined crystal form improves PDE3/PDE4 inhibitor solubility, stability, and inhaled COPD efficacy while reducing clearance limits.

A benzo-fused CYP11B2 inhibitor selectively lowers aldosterone to address refractory hypertension without the hyperkalemia risk of existing inhibitors.

A sugar alcohol and potassium ratio helps milk-derived sphingomyelin solids retain milk flavor and suppress off-flavors during storage.

Controlled crystallization of vericiguat polymorphs improves processing, stability, dissolution, and bioavailability for formulation.

Chemically modified dsRNA targets conserved HBV genome regions to suppress multiple viral genes, lower viral load, and support immune control.

Multiple WX-216 sodium salt crystal forms improve solubility, stability, and manufacturability for influenza antiviral API development.

Novel ATX inhibitor compounds lower LPA levels to block pathological processes in fibrosis, inflammation, neurodegeneration, and cancer.

HPK1 inhibition with isoquinoline compounds boosts anti-tumor immunity while reducing healthy-cell damage and resistance limits.

Steroid-containing lipid nanoparticles shift nucleic acid delivery from passive liver uptake to spleen targeting, reducing off-target organ toxicity.

Deuterium substitution improves PA endonuclease inhibitor stability and antiviral activity against influenza A and B, including resistant strains.

A cross-linked hyaluronan gel and fluid blend keeps triamcinolone mixtures stable after heat sterilization while preserving viscoelasticity.

A self-assembling diclofenac nanoemulsion improves skin penetration and phase stability without permeation enhancers or high-energy processing.

Novel labelled compounds selectively bind alpha-synuclein aggregates for PET imaging, improving diagnosis and disease progression monitoring.

Purine derivatives tune DNA-PK inhibition to boost chemo- and radiosensitization in tumor cells while limiting toxicity and off-target effects.

By blocking the FimH mannose-binding site, C-mannosides reduce UPEC colonization and invasion without relying on conventional antibiotics.

Small molecules modulate and stabilize PanK to control CoA levels, enabling study and treatment of PKAN, diabetes, and related disorders.

Synthetic nanocarriers carrying rapamycin reduce anti-drug antibodies to uricase, lowering serum uric acid and gout flares.

Structural glucosamine prodrugs improve oral bioavailability and half-life, supporting stronger bone and joint therapy with lower clearance.

ADH, AKR, and SNO-CoAR inhibition raises cardiac SNO levels to reduce oxidative stress and limit MI/R-induced myocardial damage.

Novel 13-membered azaketolides modify the macrolide scaffold to retain potent activity against drug-resistant Gram-negative bacteria.

METTL7A overexpression boosts stem cell viability and osteogenic differentiation, improving bone regeneration in severe defects with vascular damage.

Rigid nanobowl support helps liposomes resist plasma proteins and blood shear, reducing drug leakage and improving tumor delivery.

RNA origami aptamers inhibit thrombin while increasing molecular size to improve pharmacokinetics and enable antidote-controlled anticoagulation.